Daniel PT - Search Results

1

In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.

Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT. Sturm I, et al. Among authors: daniel pt. BMC Cancer. 2005 Aug 18;5:105. doi: 10.1186/1471-2407-5-105. BMC Cancer. 2005. PMID: 16109171 Free PMC article.

2

Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation.

Sturm I, Bosanquet AG, Radetzki S, Hummel M, Dörken B, Daniel PT. Sturm I, et al. Among authors: daniel pt. Int J Cancer. 2006 May 1;118(9):2329-36. doi: 10.1002/ijc.21535. Int J Cancer. 2006. PMID: 16331630

3

Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.

Sturm I, Rau B, Schlag PM, Wust P, Hildebrandt B, Riess H, Hauptmann S, Dörken B, Daniel PT. Sturm I, et al. Among authors: daniel pt. BMC Cancer. 2006 May 10;6:124. doi: 10.1186/1471-2407-6-124. BMC Cancer. 2006. PMID: 16686938 Free PMC article.

4

Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene.

Sturm I, Papadopoulos S, Hillebrand T, Benter T, Lück HJ, Wolff G, Dörken B, Daniel PT. Sturm I, et al. Among authors: daniel pt. Int J Cancer. 2000 Aug 15;87(4):517-21. doi: 10.1002/1097-0215(20000815)87:4<517::aid-ijc9>3.0.co;2-b. Int J Cancer. 2000. PMID: 10918191

5

Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.

Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dörken B, Daniel PT. Hermann S, et al. Among authors: daniel pt. Int J Cancer. 2001 Jun 15;92(6):805-11. doi: 10.1002/ijc.1284. Int J Cancer. 2001. PMID: 11351299

6

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.

Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Sturm I, et al. Among authors: daniel pt. Cell Death Differ. 2003 Apr;10(4):477-84. doi: 10.1038/sj.cdd.4401194. Cell Death Differ. 2003. PMID: 12719725

7

Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.

Reimer TA, Anagnostopoulos I, Erdmann B, Lehmann I, Stein H, Daniel P, Dörken B, Rehm A. Reimer TA, et al. BMC Cancer. 2005 May 17;5:47. doi: 10.1186/1471-2407-5-47. BMC Cancer. 2005. PMID: 15904507 Free PMC article.

8

The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines.

Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel PT. Radetzki S, et al. Among authors: daniel pt. Oncogene. 2002 Jan 10;21(2):227-38. doi: 10.1038/sj.onc.1205010. Oncogene. 2002. PMID: 11803466

9

Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.

Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT. Schelwies K, et al. Among authors: daniel pt. Int J Cancer. 2002 Jun 1;99(4):589-96. doi: 10.1002/ijc.10380. Int J Cancer. 2002. PMID: 11992551

10

Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.

Güner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M, Daniel PT. Güner D, et al. Among authors: daniel pt. Int J Cancer. 2003 Feb 10;103(4):445-54. doi: 10.1002/ijc.10850. Int J Cancer. 2003. PMID: 12478659

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters